Skip to Content

Optimisation of knowledge and resources for the formulation of PRD vaccines

Work Package Leader

World Health Organization/ Global Adjuvant Development Initiative - Dr Martin Friede

Objectives  

  • To set-up the European branch of the global Adjuvant network ADJUNET, between groups developing adjuvants and public sector organisations evaluating adjuvants in clinical trials.
  • To contribute to the Global Adjuvant Development Initiative by providing the first European resource for sharing information and facilitating communication between groups developing adjuvants and public sector organisations evaluating adjuvants in clinical trials, including the EC funded integrated project for malaria and tuberculosis vaccines, EMVDA and TBVAC, as well as existing networks such as the European Adjuvant Advisory Committee.
  • To analyse the needs and the gaps in the development of PRD vaccines formulated with adjuvants. Among others, a special attention will be given to 1) the need of standardised evaluation, 2) the identification of technical gaps in optimising antigens to obtain high quality antigens with well defined physico-chemical characteristics, standardised immunologic read-outs, 3) the identification of need of SPF facilities necessary for minimising inconsistency due to viral infection.
  • To develop a strategy specific to Malaria and Tuberculosis vaccines for the optimisation of the immune response with adjuvants, in order to guide the vaccine developers for better cost-effectiveness pharmaceutical development and clinical development, based on the assessment of the different alternatives of formulation work in the course of the clinical development.
  • To develop a training program for European PRD vaccine developers and members of ADJUNET to be implemented by Martin Friede (WHO-GADI).

Deliverables

D2.1 Report on needs and gaps for the optimisation of immune response of PRD vaccines

D2.2 Training programme on optimisation of vaccines with adjuvants